Qi Cui, AGS 2021: The GLP-1R Agonist NLY01 Reduces Neuroinflammation and Protects against RGC Loss in a Preclinical Glaucoma Model

We were delighted to catch up with Dr Qi Cui (Scheie Eye Institute, University of Pennsylvania, PA, USA), who told us about her research on the GLP-1R agonist NLY01 and the next steps for clinical development.

Questions

1. What is NLY01 and what is the rationale for its use in glaucoma therapy? (00:20)
2. Could you give us an overview of your study and its findings? (01:31)
3. What will be the next steps in the clinical development of NLY01? (02:46)

Speaker Disclosure: Qi Cui discloses the following: Patent (pending): Penn Center for Innovation; Sponsored Research: Neuraly, Inc., NIH/NEI K08EY029765.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of AGS 2021.